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Blastic plasmacytoid dendritic
cell neoplasm with extensive
cutaneous and central nervous
system involvement
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Abstract
Blastic plasmacytoid dendritic neoplasm is
an exceedingly rare tumor that has undergone
several changes in nomenclature over the last
two decades, largely because of confusion
regarding its cell of origin. It does, however,
have distinctive clinical features with a partic-
ularly aggressive clinical course and no stan-
dard treatment. Overall, prognosis is poor and
relapse is routine after initial response to
chemotherapy. In this report, we describe a
typical patient with this disease and reconcile
the available literature and its evolution. We
emphasize the leukemic nature of this tumor’s
behavior, with extensive central nervous sys-
tem and skin involvement, and describe for the
first time a potential role for maintenance
chemotherapy in its treatment.
Case Report
A 69 year old Caucasian man from Texas
(USA) presented with several months history
of a diffuse skin rash. He also reported fatigue
and a 10 pound weight loss over the same peri-
od of time. The rash initially involved the
trunk, but later progressively extended to his
extremities and face, and was only associated
with minimal pruritus. His past medical histo-
ry was remarkable for coronary artery disease,
congestive heart failure, and mild chronic
renal insufficiency. On physical examination,
he had a diffuse, pigmented, plaque-like,
bruised rash over his trunk, extremities, and
face (Figure 1). He was also noted to have a
low grade temperature of 100 degrees
Fahrenheit (37.8°C) and mildly enlarged, non-
tender epitrochlear and cervical lymph nodes.
Laboratory evaluation was remarkable for a
white blood cell count of 32,000 with 50%
blasts. Hemoglobin was 12.5 g/dL, platelets
357,000/dL, and lactate dehydrogenase (LDH)
was elevated at 473 (normal range 100-190).
Review of his peripheral blood smear revealed
the presence of large basophilic cells with
agranular cytoplasm, cleaved nuclei with a
high nuclear cytoplasmic ratio, and prominent
discrete nucleoli (Figure 2A). Because of the
leukemic nature of his disease, cerebrospinal
fluid (CSF) analysis was done and revealed the
presence of immature appearing blasts; simi-
lar to the peripheral blood findings (Figure
2B). Biopsy of a one of the skin lesions showed
diffuse perivascular and peri-adnexal infiltra-
tion by a monomorphic population of medium
to large malignant-appearing cells, with convo-
luted nuclei and prominent nucleoli, similar in
appearance to the cells present in the circula-
tion and CSF (Figure 3). Bone marrow biopsy
and aspirate specimens were markedly hyper-
cellular with diffuse infiltration of immature
blasts similar to the skin and peripheral blood
(not shown). On flow cytometry of peripheral
blood the malignant cells were positive for
CD4, CD7, CD45, CD56, and HLA-DR. The
same cell population was negative for CD2,
CD3, CD5, CD8, CD10, CD13, CD14, CD19,
CD22, CD23, CD33, CD34, FMC7, and for both
kappa and lambda light chains. Terminal
deoxynucleotidyl transferase (TdT) was dif-
fusely positive by immunohistochemistry in
both the skin and bone marrow. CD45 was also
diffusely positive, with moderate to strong
staining intensity. Further molecular studies
of the malignant cells showed no clonal T cell
receptor (TCR) re-arrangement present and
Ebstein Barr Virus (EBV) early RNA elements
(EBER) were negative. Testing for serum anti-
bodies for HTLV-I and HTLV-II was negative.
Cytogenetic analysis of the bone marrow aspi-
rate showed normal male karyotype. Imaging
studies, including brain and sinus magnetic
resonance imaging (MRI), were all negative
except for the presence of a mildly enlarged
spleen. 
Based on the clinical presentation and the
profile of the malignant cells, the patient was
diagnosed with acute Natural Killer Cell lym-
phoblastic Leukemia (NK-ALL) (based on the
prevailing diagnostic nomenclature, later
renamed blastic plasmacytoid dendritic cell
neoplasm). The absence of myeloid (CD13,
CD33), T cell (CD2, CD3, TCR rearrangement)
and B cell (CD19, CD10, CD22, immunoglobu-
lin light chains) markers essentially restricted
the differential to monocytic and BPDC neo-
plasms. Human monocytes express dim CD4
and monocytic leukemias have the tendency to
infiltrate extrahematopoietic tissues. In his
case, the size of the cells, the absence of cyto-
plasmic azurophilic granules and the morphol-
ogy of the nuclei and the absence of CD14 as
well as the positivity for TdT and the presence
of CD7, essentially excluded the possibility of
monocytic/monoblastic leukemia. The patient
was started on COP (cyclophosphamide 600
mg/m2 IV on day 1, vincristine 2 mg IV on day
1, and prednisone 100 mg per mouth daily on
days 1-5) repeated every 21 days, along with
weekly intrathecal methotrexate. The schedule
was selected because of his borderline per-
formance status and multiple significant
comorbidities. Doxorubicin was not adminis-
tered because of known congestive heart fail-
ure. There was a rapid clinical response to
treatment, with complete disappearance of
leukemic blasts from the blood and CSF, and
fading of the skin lesions. No tumor lysis was
observed and treatment was well-tolerated
with no significant toxicities. After 3 cycles of
intravenous COP chemotherapy and 6
intrathecal methotrexate treatments, repeat
biopsy of an old skin lesion site and bone mar-
row biopsy were both negative for malignant
cells. Leukemic blasts also disappeared from
the CSF after the 1st intrathecal methotrexate
with no later reappearance during subsequent
follow up. Repeat flow cytometry of the bone
marrow showed complete disappearance of the
malignant clone and the patient was therefore
declared to be in complete remission. Because
of the known markedly increased risk of
relapse reported with this type of malignancy
and because of its clinical behavior resembling
that of acute lymphoblastic leukemia, the
patient was placed on maintenance
chemotherapy with monthly POMP (pred-
nisone 100 mg po (per os) day 1-5, vincristine
2 mg IV on day 1, methotrexate 20 mg po once
a week, and 6-mercaptopurine 100 mg po
daily) along with monthly intrathecal
methotrexate. This regimen was administered
for 8 months altogether, during which time
repeat assessments showed continued com-
plete remission, but was subsequently discon-
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tinued because of recurrent pancytopenia and
decreased patient tolerance. Unfortunately,
two months after POMP was discontinued, the
patient experienced widespread recurrence of
his leukemia and succumbed to his illness. 
Discussion and Conclusions
Blastic plasmacytoid dendritic cell neoplasm
(BPDCN) is an exceedingly rate neoplasm that
was reported under multiple different names
in the literature, reflecting a mix of clinical
descriptive terminology and some confusion
about the cell of origin. The most recent
nomenclature of BPDCN is reported in the
updated World Health Organization classifica-
tion and conforms to the proposed cell of ori-
gin.1 Originally, it was named blastic natural
killer cell leukemia because of suspected ori-
gin at that time and later changed to
CD4+/CD56+ hematodermotropic tumor
(HDT),2 before the most current classification.
Blastic plasmacytoid dendritic cell neoplasm
primarily affects middle-aged or elderly indi-
viduals, with male predominance, and a pecu-
liar predilection for skin involvement, where it
forms nodules, plaques and patches of variable
sizes. Bone marrow, peripheral blood, lymph
nodes and soft tissues are commonly involved,
but CNS involvement is more unusual and
reported in only a few cases.3,4 The term blastic
was initially adopted because the tumor is
composed of medium to large-sized cells with
fine chromatin and scanty cytoplasm resem-
bling lymphoblasts, or in some cases,
myeloblasts,5 and may on occasion exhibit sub-
membranous cytoplasmic vacuolations sur-
rounding the nucleus. The leukemic cells are
usually agranular, and angiodestructive or
necrotic lesions are rare. EBV is negative in all
cases and TCR genes are typically in germline
configuration with no rearrangement seen.
Tumor cells are invariably CD4+ and CD56+,
and usually HLA-DR and CD45RA are positive
as well. CD2 and CD34 are usually negative;
and expression of TdT, CD7 and cytoplasmic
CD3  is variable. Although in earlier reports,
this tumor was originally referred to as blastic
NK lymphoma, or cutaneous CD-4 positive lym-
phoma as noted earlier,5-9 the natural killer ref-
erence in the nomenclature was subsequently
removed because of the absence of EBV
genomic material or antigens in the tumor
cells in which the expression of CD4 which is
not considered a NK cell marker. The absence
of cytotoxic molecules, like TIA-1, granzyme B
and perforin, raised more questions regarding
the origin of this tumor, and it was later found
that these CD4+/CD56+ tumors actually
express IL-3 receptor alpha (CD123) and the T-
cell leukemia-1 (TCL1) molecule, both consid-
ered plasmacytoid dendritic cell (pDC) mark-
                             Case Report
Figure 1. A plaque-like pigmented bruised rash over the patient’s trunk (A) and face (B).
Figure 2. Large malignant-appearing cells, with agranular cytoplasm, cleaved nuclei and
prominent neocleoli on peripheral blood smear using Wright stain (A) and similar blast
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ers, along with other related pDC markers; the
blood dendritic cell antigen 2 (BDCA-2) and
interferon.10 Most authorities, therefore, agree
that BPDCN is a pDC precursor-related and not
a true NK neoplasm. It is worthwhile noting
that there is no pathognomonic cytogenetic
abnormality, but deletion in 5q- is the most fre-
quent associated cytogenetic change.7
Clinically, patients with BPDCN have a poor
prognosis and usually survive on average a lit-
tle more than one year after the diagnosis is
made. Typically, initial response to treatment
is dramatic (70% complete response and 10%
partial response), but later tumor cells become
resistant. CHOP or COP-like regimens have
been mainly used, as well as regimens for
acute leukemia, but almost all patients relapse
after initial response and eventually succumb
to the disease. Maintenance chemotherapy,
such as what was used in this case, may be
critical in long term control of this leukemia,
similar to other non-myelogenic leukemias,
but has not been well studied. We believe that
maintenance chemotherapy may be critical in
preventing the inevitable rapid relapse of this
tumor after initial therapy and could be a rea-
sonable consideration to help maintain pro-
longed freedom from disease relapse. 
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Figure 3. Hematoxylin & Eosin stain of skin lesion biopsy. Low power view of leukemic
infiltrate corresponding to the raised plaque (A, black arrows) and high power view of
the malignant cells in the skin infiltrate (B). 
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